L
Lee S. Simon
Researcher at Harvard University
Publications - 186
Citations - 18635
Lee S. Simon is an academic researcher from Harvard University. The author has contributed to research in topics: Clinical trial & Randomized controlled trial. The author has an hindex of 50, co-authored 180 publications receiving 17441 citations. Previous affiliations of Lee S. Simon include University of Texas Southwestern Medical Center & University of Bristol.
Papers
More filters
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Cyclooxygenase in biology and disease
Raymond N. DuBois,Steven B. Abramson,Leslie J. Crofford,Rajnish A. Gupta,Lee S. Simon,Leo B A van de Putte,Peter E. Lipsky +6 more
TL;DR: The current understanding of the role of cyclooxygenase‐1 and ‐2 in different physiological situations and disease processes ranging from inflammation to cancer is summarized.
Journal ArticleDOI
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson,David T. Felson,Josef S Smolen,George A. Wells,Bi Zhang,Lilian H D van Tuyl,Julia Funovits,Daniel Aletaha,Cornelia F Allaart,Joan M. Bathon,Joan M. Bathon,Stefano Bombardieri,Peter Brooks,Andrew K Brown,Marco Matucci-Cerinic,Hyon K. Choi,Bernard Combe,Maarten de Wit,Maxime Dougados,Paul Emery,Daniel E. Furst,Juan J. Gomez-Reino,Gillian A. Hawker,Edward C. Keystone,Dinesh Khanna,John R. Kirwan,Tore K Kvien,Robert Landewé,Joachim Listing,Kaleb Michaud,Emilio Martín-Mola,Pamela Montie,Theodore Pincus,Pamela Richards,Jeffrey Siegel,Jeffrey Siegel,Lee S. Simon,Tuulikki Sokka,Vibeke Strand,Peter Tugwell,Alan Tyndall,Désirée van der Heijde,S. M. M. Verstappen,Barbara White,Frederick Wolfe,Angela Zink,Maarten Boers +46 more
TL;DR: It is proposed that a patient's RA can be defined as being in remission based on one of two definitions: (1) when scores on the tender joint count, swollen joint counts, CRP level, and patient global assessment are all ≤1, or (2) when the score on the Simplified Disease Activity Index is ≤3.
Journal ArticleDOI
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis : A randomized controlled trial
Lee S. Simon,Arthur L. Weaver,David Y. Graham,A J Kivitz,Peter E. Lipsky,Richard C. Hubbard,Peter C. Isakson,Kenneth M. Verburg,Shawn S. Yu,William W. Zhao,G S Geis +10 more
TL;DR: All dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen.
Journal ArticleDOI
OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.
T. Pham,D. van der Heijde,Roy D. Altman,Jennifer J. Anderson,Nicholas Bellamy,Marc C. Hochberg,Lee S. Simon,Vibeke Strand,Thasia G. Woodworth,Maxime Dougados +9 more
TL;DR: This data driven and experts' opinion approach is the basis for proposing an optimal simplified set of responder criteria for OA clinical trials.